|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacher M, Schrader J, Thompson N, Kuschela
K, Gemsa D, Waeber G and Schlegel J: Up-regulation of macrophage
migration inhibitory factor gene and protein expression in glial
tumor cells during hypoxic and hypoglycemic stress indicates a
critical role for angiogenesis in glioblastoma multiforme. Am J
Pathol. 162:11–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fritz L, Dirven L, Reijneveld JC, Koekkoek
JA, Stiggelbout AM, Pasman HR and Taphoorn MJ: Advance care
planning in glioblastoma patients. Cancers (Basel). 8:1022016.
View Article : Google Scholar
|
|
4
|
Huang B, Zhang H, Gu L, Ye B, Jian Z,
Stary C and Xiong X: Advances in immunotherapy for glioblastoma
multiforme. J Immunol Res. 2017:35976132017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reardon DA, Wen PY, Wucherpfennig KW and
Sampson JH: Immunomodulation for glioblastoma. Curr Opin Neurol.
30:361–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Srinivasan VM, Ferguson SD, Lee S,
Weathers S-P, Kerrigan BCP and Heimberger AB: Tumor vaccines for
malignant gliomas. Neurotherapeutics. 14:345–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanders S and Debinski W: Challenges to
successful implementation of the immune checkpoint inhibitors for
treatment of glioblastoma. Int J Mol Sci. 21:212020. View Article : Google Scholar
|
|
8
|
Aran D, Hu Z and Butte AJ: xCell:
Digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 18:2202017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Larkin J, Chiarion-Sileni V, González R,
Grob J, Cowey C and Lao C: Combined nivolumab and ipilimumab or
monotherapy in previously untreated melanoma. N Engl J Med.
373:23–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Massari F, Santoni M, Ciccarese C, Santini
D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R,
Montironi R, et al: PD-1 blockade therapy in renal cell carcinoma:
Current studies and future promises. Cancer Treat Rev. 41:114–121.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan AC, Heimberger AB and Khasraw M:
Immune checkpoint inhibitors in gliomas. Curr Oncol Rep. 19:232017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Desai K, Hubben A and Ahluwalia M: The
role of checkpoint inhibitors in glioblastoma. Target Oncol.
14:375–394. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caccese M, Indraccolo S, Zagonel V and
Lombardi G: PD-1/PD-L1 immune-checkpoint inhibitors in
glioblastoma: A concise review. Crit Rev Oncol Hematol.
135:128–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gustafsson M, Edström M, Gawel D, Nestor
CE, Wang H, Zhang H, Barrenäs F, Tojo J, Kockum I, Olsson T, et al:
Integrated genomic and prospective clinical studies show the
importance of modular pleiotropy for disease susceptibility,
diagnosis and treatment. Genome Med. 6:172014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fagone P, Mazzon E, Cavalli E, Bramanti A,
Petralia MC, Mangano K, Al-Abed Y, Bramati P and Nicoletti F:
Contribution of the macrophage migration inhibitory factor
superfamily of cytokines in the pathogenesis of preclinical and
human multiple sclerosis: In silico and in vivo evidences. J
Neuroimmunol. 322:46–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mangano K, Cavalli E, Mammana S, Basile
MS, Caltabiano R, Pesce A, Puleo S, Atanasov AG, Magro G, Nicoletti
F, et al: Involvement of the Nrf2/HO-1/CO axis and therapeutic
intervention with the CO-releasing molecule CORM-A1, in a murine
model of autoimmune hepatitis. J Cell Physiol. 233:4156–4165. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mammana S, Bramanti P, Mazzon E, Cavalli
E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F and
Mangano K: Preclinical evaluation of the PI3K/Akt/mTOR pathway in
animal models of multiple sclerosis. Oncotarget. 9:8263–8277. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fagone P, Muthumani K, Mangano K, Magro G,
Meroni PL, Kim JJ, Sardesai NY, Weiner DB and Nicoletti F: VGX-1027
modulates genes involved in lipopolysaccharide-induced Toll-like
receptor 4 activation and in a murine model of systemic lupus
erythematosus. Immunology. 142:594–602. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nicoletti F, Mazzon E, Fagone P, Mangano
K, Mammana S, Cavalli E, Basile MS, Bramanti P, Scalabrino G, Lange
A, et al: Prevention of clinical and histological signs of
MOG-induced experimental allergic encephalomyelitis by prolonged
treatment with recombinant human EGF. J Neuroimmunol. 332:224–232.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fagone P, Mazzon E, Mammana S, Di Marco R,
Spinasanta F, Basile MS, Petralia MC, Bramanti P, Nicoletti F and
Mangano K: Identification of CD4+ T cell biomarkers for
predicting the response of patients with relapsing-remitting
multiple sclerosis to natalizumab treatment. Mol Med Rep.
20:678–684. 2019.PubMed/NCBI
|
|
22
|
Fagone P, Mangano K, Coco M, Perciavalle
V, Garotta G, Romao CC and Nicoletti F: Therapeutic potential of
carbon monoxide in multiple sclerosis. Clin Exp Immunol.
167:179–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patti F, Cataldi ML, Nicoletti F, Reggio
E, Nicoletti A and Reggio A: Combination of cyclophosphamide and
interferon-β halts progression in patients with rapidly
transitional multiple sclerosis. J Neurol Neurosurg Psychiatry.
71:404–407. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Presti M, Mazzon E, Basile MS, Petralia
MC, Bramanti A, Colletti G, Bramanti P, Nicoletti F and Fagone P:
Overexpression of macrophage migration inhibitory factor and
functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in
glioblastoma. Oncol Lett. 16:2881–2886. 2018.PubMed/NCBI
|
|
25
|
Fagone P, Caltabiano R, Russo A, Lupo G,
Anfuso CD, Basile MS, Longo A, Nicoletti F, De Pasquale R, Libra M,
et al: Identification of novel chemotherapeutic strategies for
metastatic uveal melanoma. Sci Rep. 7:445642017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basile MS, Mazzon E, Russo A, Mammana S,
Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti
F, et al: Differential modulation and prognostic values of
immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mangano K, Mazzon E, Basile MS, Di Marco
R, Bramanti P, Mammana S, Petralia MC, Fagone P and Nicoletti F:
Pathogenic role for macrophage migration inhibitory factor in
glioblastoma and its targeting with specific inhibitors as novel
tailored therapeutic approach. Oncotarget. 9:17951–17970. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nicoletti F, Fagone P, Meroni P, McCubrey
J and Bendtzen K: mTOR as a multifunctional therapeutic target in
HIV infection. Drug Discov Today. 16:715–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rothweiler F, Michaelis M, Brauer P, Otte
J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, et
al: Anticancer effects of the nitric oxide-modified saquinavir
derivative saquinavir-NO against multidrug-resistant cancer cells.
Neoplasia. 12:1023–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A,
Hoon DSB, Vera JC, Heiss JD, Chen CC, et al: B7-H4(B7×)-mediated
cross-talk between glioma-initiating cells and macrophages via the
IL6/JAK/STAT3 pathway lead to poor prognosis in glioma patients.
Clin Cancer Res. 22:2778–2790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua
W, Xu M, Zhong P, Yu S, Chen D, et al: Molecular subgroups and
B7-H4 expression levels predict responses to dendritic cell
vaccines in glioblastoma: An exploratory randomized phase II
clinical trial. Cancer Immunol Immunother. 67:1777–1788. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moertel CL, Xia J, LaRue R, Waldron NN,
Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, et
al: CD200 in CNS tumor-induced immunosuppression: The role for
CD200 pathway blockade in targeted immunotherapy. J Immunother
Cancer. 2:462014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang CY, Hsieh YT, Fang KM, Yang CS and
Tzeng SF: Reduction of CD200 expression in glioma cells enhances
microglia activation and tumor growth. J Neurosci Res.
94:1460–1471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Olin MR, Ampudia-Mesias E, Pennell CA,
Sarver A, Chen CC, Moertel CL, Hunt MA and Pluhar GE: Treatment
combining CD200 immune checkpoint inhibitor and tumor-lysate
vaccination after surgery for pet dogs with high-grade glioma.
Cancers (Basel). 11:1372019. View Article : Google Scholar
|
|
35
|
Sloan KE, Stewart JK, Treloar AF, Matthews
RT and Jay DG: CD155/PVR enhances glioma cell dispersal by
regulating adhesion signaling and focal adhesion dynamics. Cancer
Res. 65:10930–10937. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hung AL, Maxwell R, Theodros D, Belcaid Z,
Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, et al:
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity
and survival in GBM. OncoImmunology. 7:e14667692018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li F, Lv B, Liu Y, Hua T, Han J, Sun C, Xu
L, Zhang Z, Feng Z, Cai Y, et al: Blocking the CD47-SIRPα axis by
delivery of anti-CD47 antibody induces antitumor effects in glioma
and glioma stem cells. OncoImmunology. 7:e13919732018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Wu X, Wang Y, Li Y, Chen X, Yang W
and Jiang L: CD47 promotes human glioblastoma invasion through
activation of the PI3K/Akt pathway. Oncol Res. 27:415–422. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang M, Hutter G, Kahn SA, Azad TD,
Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, et
al: Anti-CD47 treatment stimulates phagocytosis of glioblastoma by
M1 and M2 polarized macrophages and promotes M1 polarized
macrophages in vivo. PLoS One. 11:e01535502016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
von Roemeling CA, Wang Y, Qie Y, Yuan H,
Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, et al: Therapeutic
modulation of phagocytosis in glioblastoma can activate both innate
and adaptive antitumour immunity. Nat Commun. 11:15082020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han MZ, Wang S, Zhao WB, Ni SL, Yang N,
Kong Y, Huang B, Chen AJ, Li XG, Wang J, et al: Immune checkpoint
molecule herpes virus entry mediator is overexpressed and
associated with poor prognosis in human glioblastoma. EBioMedicine.
43:159–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Malissen N, Macagno N, Granjeaud S,
Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M,
Guillot B, Pasero C, et al: HVEM has a broader expression than
PD-L1 and constitutes a negative prognostic marker and potential
treatment target for melanoma. OncoImmunology. 8:e16659762019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li G, Hu YS, Li XG, Zhang QL, Wang DH and
Gong SF: Expression and switching of TH1/TH2 type cytokines gene in
human gliomas. Chin Med Sci J. 20:268–272. 2005.PubMed/NCBI
|
|
44
|
Jahan N, Talat H, Alonso A, Saha D and
Curry WT: Triple combination immunotherapy with GVAX, anti-PD-1
monoclonal antibody, and agonist anti-OX40 monoclonal antibody is
highly effective against murine intracranial glioma.
OncoImmunology. 8:e15771082019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jahan N, Talat H and Curry WT: Agonist
OX40 immunotherapy improves survival in glioma-bearing mice and is
complementary with vaccination with irradiated GM-CSF-expressing
tumor cells. Neuro-oncol. 20:44–54. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Taube JM, Galon J, Sholl LM, Rodig SJ,
Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, et
al: Implications of the tumor immune microenvironment for staging
and therapeutics. Mod Pathol. 31:214–234. 2018. View Article : Google Scholar : PubMed/NCBI
|
